-continued

```
Ala Arg Leu Phe Arg Ser Ser Ser Lys Gly Phe Gln Gly Thr Thr Gln
            580                 585                 590

Thr Ser His Gly Ser Leu Met Thr Asn Lys Gln His Gln Gly Lys Ser
        595                 600                 605

Asn Asn Gln Tyr Tyr His Gly Lys Lys Arg Lys His Lys Arg Asp Ala
    610                 615                 620

Pro Leu Ser Asp Leu Cys Arg
625                 630
```

What is claimed is:

1. A method of treating a disease or condition selected from

(1) a disorder associated with telomere or telomerase dysfunction;

(2) a disorder associated with aging;

(3) a pre-leukemic or pre-cancerous condition; and

(4) neurodevelopmental disorder

in a subject in need thereof; the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I):

(I)



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from O, S, N—OH, N—C_{1-3} alkoxy, N—NH_2, and N—CN;

W is selected from $C(O)OR^{a1}$, $C(O)NR^{c1}R^{d1}$, $C(O)NR^{c1}S(O)_2R^{b1}$, $C(O)NR^{c1}OR^{a1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, OR^{a1}, $NR^{c1}R^{d1}$, $NR^{c1}S(O)_2R^{b1}$, $B(OH)_2$, $P(=O)(OR^{a1})_2$, halo, CN, Cy, and a carboxylic acid bioisostere;

or R^1 and W together with the carbon atoms to which they are attached from a monocyclic 4-7 membered heterocycloalkyl ring or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from R^{Cy};

X is selected from N and CR^2;

Y is selected from N and CR^3;

R^2 is selected from H, Cy, halo, CN, NO_2, OR^{a1}, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy, halo, CN, NO_2, OR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}S(O)_2R^{b1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$;

R^3 is selected from H, Cy, halo, CN, NO_2, OR^{a1}, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy, halo, CN, NO_2, OR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}S(O)_2R^{b1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$.

ring A, together with N and other atom or atoms that ring A shares with ring B, is selected from a monocyclic C_{3-7} cycloalkyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, a phenyl ring, and a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R^A;

ring B, together with the atom or atoms that ring B shares with ring A, is selected from a monocyclic C_{3-7} cycloalkyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, a phenyl ring, and a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R^B;

each R^A is independently selected from H, Cy, halo, CN, NO_2, OR^{a1}, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy, halo, CN, NO_2, OR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}S(O)_2R^{b1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$;

or any two R^A groups together with the atom or atoms to which they are attached form ring C, which is selected from a monocyclic C_{3-7} cycloalkyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, a phenyl ring, and a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R^C;

each R^B is independently selected from H, Cy, halo, CN, NO_2, OR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}S(O)_2R^{b1}$, $S(O)_2R^{b1}$, $S(O)_2NR^{c1}R^{d1}$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy, halo, CN, NO_2, OR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}S(O)_2R^{b1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$;

or any two R^B groups together with the atom or atoms to which they are attached form ring D, which is selected from a monocyclic C_{3-7} cycloalkyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, a phenyl ring, and a monocyclic 5-6 membered heteroaryl ring, each of